HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells

BACKGROUND: Chemotherapy resistance presents a difficult challenge in treating epithelial ovarian cancer patients, particularly when tumors exhibit resistance to multiple chemotherapeutic agents. A few studies have shown that elevated serum levels of the ovarian cancer biomarker HE4 correlate with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro, J. R., Schorl, C., Yano, N., Romano, N., Kim, K. K., Singh, R. K., Moore, R. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869286/
https://www.ncbi.nlm.nih.gov/pubmed/27184254
http://dx.doi.org/10.1186/s13048-016-0240-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869286/
https://www.ncbi.nlm.nih.gov/pubmed/27184254
http://dx.doi.org/10.1186/s13048-016-0240-0

Ejemplares similares